Employees at Earlens rank William Facteau in the Top 10% of CEOs in San Francisco. Comparatively, employees at Zimmer Biomet rank Ivan Tornos in the Top 30% of CEOs in Fort Wayne, IN. Employees rate their CEO differently based on the frequency of interaction, ability to affect company culture, and drive measurable results.

William Facteau

CEO of Earlens

BIO: Bill Facteau is a medical device executive with 30 years of experience in the industry. He currently serves on the Boards of Earlens and Aerin Medical. In Nov 2013, Facteau joined Earlens as President & CEO. Prior to Earlens, Facteau held positions as Vice Chairman of ExploraMed and an Entrepreneur in Residence at NEA, respectively. He was Chairman of the Board for Cabochon Aesthetics and a board member at NeoTract and CV Ingenuity prior to their acquisitions. From 2004-2010, Facteau served as President & CEO of Acclarent. Under his leadership, the company went from concept to acquisition in 5 years, raised over $100M and grew revenues to $100M. After the $800M acquisition by J&J, Mr. Facteau served as WW President of their ENT Division from 2010-2012. Prior to Acclarent, Facteau was GM of the Endovascular Division at Abbott Vascular. He joined Abbott via the $683 million acquisition of Perclose, where he was Sales Director. From 1993-1998, he worked at US Surgical. Mr. Facteau received his BA in Political Science from the Univ. of Connecticut.

Ivan Tornos

CEO of Zimmer Biomet

BIO: Three decades of Global Medical Device, Diagnostics, Biotechnology, and Pharmaceutical Sales, Marketing, Business Development, Strategy, Leading People, NPD, and General Management experience with Fortune 50 to 500 companies, med tech start-ups, and incubator projects. Proven track record in US Biotech, Pharmaceutical and Medical Device Industry, Latin America Medical Devices and Pharmaceuticals, US Diagnostics, APAC Medical Devices, and EMEA Medical Devices and Pharma/Medical Supplies. Robust experience in B2B strategy and business development in clinical, consumer, hospital, ASC and research markets. Have been directly accountable for P&L operations/businesses in several countries/regions/continents ranging from $25M to ~$9 Billion+